Differential resistance of melanoma cells to treatment with recombinant IFN-α2b and Leukocyte IFN

Anticancer Research

Volumn 27, Issue 4 B, 2007, Pages 2109-2114

  Ruuth, Krishna ^a   Berglund, Åsa ^b   Munoz, Varinia ^c   Lundgren, Erik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b BioNative AB   (Sweden)

^c Viragen (Scotland) Ltd   (United Kingdom)

Author keywords

IFN ; Interferon; Melanoma cell line

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; MULTIFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CULTURE; CELL LINE; CELL PROLIFERATION; CELL STRUCTURE; CELL SURVIVAL; COLONY FORMATION; COMPARATIVE STUDY; CONTROLLED STUDY; GROWTH RATE; HUMAN; HUMAN CELL; LEUKOCYTE; MELANOMA CELL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL GROWTH PROCESSES; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERFERON ALFA-2B; INTERFERON-ALPHA; MELANOMA; TUMOR CELLS, CULTURED;

EID: 34547757538     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Stoutenburg JP, Schrope B and Kaufman HL: Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 4: 823-835, 2004.
2. Chin L: The genetics of malignant melanoma: lessons from mouse and man. Nat Rev Cancer 3(8): 559-570, 2003.
3. Röckmann H and Schadendorf D: Drug resistance in human melanoma: mechanisms and therapeutic opportunities. Onkologie 26: 581-587, 2003.
4. Bradbury PA and Middleton MR: DNA repair pathways in drug resistance in melanoma. Anticancer Drugs 15(5): 421-426, 2004.
5. Rodolfo M, Daniotti M and Vallacchi V: Genetic progression of metastatic melanoma. Cancer Lett 214(2): 133-147, 2004.
6. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A and Suciu S: Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29(4): 241-252, 2003.
7. Hansson J: Adjuvant therapy of cutaneous melanoma - current status. Acta Oncol 45(4): 369-372, 2006.
8. Eigentler TK, Caroli UM, Radny P and Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4: 748-759, 2003.
9. Stadler R, Luger T, Bieber T et al: Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial. Acta Oncol 45(4): 389-399, 2006.
10. Krause CD and Pestka S: Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 106(3): 299-346, 2005.
11. Goren T, Kapitkovsky A, Kimchi A and Rubenstein M: High and low potency interferon-a subtypes induce (2′-5′) oligoadenylate synthetase with similar efficiency. Virology 130: 273-280, 1983.
12. Hibbert L and Foster GR: Human type I interferons differ greatly in their effects on the proliferation of primary B cells. J IFN Cytokine Res 19: 309-318, 1999.
13. Der SD, Zhou A, Williams BR and Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 95: 15623-12528, 1998.
14. Leaman DW, Chawla-Sarkar M, Jacobs B, Vyas K, Sun Y, Ozdemir A et al: Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFNbeta compared with IFN-alpha2. J Interferon Cytokine Res 23: 745-756, 2003.
15. Pansky A, Hildebrand P, Fasler-Kan E, Baselgia L, Ketterer S, Beglinger C et al: Defective Jak-STAT signal transduction pathway in melanoma cells resistant to growth inhibition by interferon-alpha. Int J Cancer 85: 720-725, 2000.
16. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM and Hilton DJ: The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 27(5): 235-241, 2002.
17. Chung CD, Liao J, Liu B et al: Specific inhibition of Stat3 signal transduction by PIAS3. Science 278(5344): 1803-1805, 1997.
18. Slutzki M, Jaitin DA, Yehezkel TB and Schreiber G: Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity. J Mol Biol 360(5): 1019-1030, 2006.